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The polyomaviruses are small DNA viruses that can establish latency in the human host. The name polyomavirus is derived from
the Greek roots poly-, which means “many,” and -oma, which means “tumours.” These viruses were originally isolated in mouse
(mPyV) and in monkey (SV40). In 1971, the ﬁrst human polyomaviruses BK and JC were isolated and subsequently demonstrated
to be ubiquitous in the human population. To date, at least nine members of the Polyomaviridae family have been identiﬁed,
some of them playing an etiological role in malignancies in immunosuppressed patients. Here, we describe the biology of human
polyomaviruses, their nonmalignant and malignant potentials ability, and their relationship with the host immune response.
1. The HumanPolyomaviruses
Polyomavirus is the sole genus of viruses within the Poly-
omaviridae family. Initially, polyomaviruses were taxonomi-
cally classiﬁed as a genus of the Papovaviridae family along
with papillomaviruses; in 2000, however, the International
Committee on Taxonomy of Viruses formally split the two
viruses into two new families, Polyomaviridae and Papillo-
maviridae [1].
The name polyomavirus is derived from the Greek roots
poly-, which means “many,” and -oma, which means “tum-
ours.”
The ﬁrst polyomavirus isolated was the mouse polyoma-
virus (mPyV) [2] causing the formation of multiple tumour
types when inoculated into newborn mice. Subsequently,
many polyomaviruses have been found to infect a variety of
vertebrate species, including rabbits, rodents, birds, nonhu-
man primates, and, to date, nine polyomaviruses have been
found in humans. The range of host species for each poly-
omavirus is very narrow, and the productive infection is lim-
ited to natural host [3].
Until 2006, BK virus (BKV) and JC virus (JCV), ﬁrst iso-
lated in 1971 [4, 5], were the only two human polyomavi-
ruses known although some evidence suggested that the sim-
ian virus 40 (SV40) could be linked to some human tumours
[6].
JCV and BKV usually infect the human population dur-
ing early childhood, and primary infection is often asymp-
tomatic. These viruses can remain latent in the kidney cells
of the host until reactivation which occurs during immun-
odepression.JCVcausesprogressivemultifocalleukoenceph-
alopathy (PML) in cases of severe immunodeﬁciency, gener-
ally due to HIV infection, whereas BKV causes nephropathy
in patients who have undergone to kidney transplants [7, 8].
SV40 does not infect naturally humans, but it was unin-
tentionally introduced in the human population through
contaminated polio vaccine in the late 1950s [6].
Lymphotropic polyomavirus (LPV) is another monkey
polyomavirus that may also infect humans, since speciﬁc
antibodies against it are present in the human population,
and LPV DNA was detected in blood from immunosup-
pressed and immunocompetent subjects [9–11].2 Clinical and Developmental Immunology
In 2007, two new human polyomaviruses were indepen-
dently described: the KI polyomavirus (KIV) at Karolinska
Institute and WU polyomavirus (WUV) the at the Washing-
ton University [12, 13]. These viruses that are closely related
toeachotherwerebothidentiﬁedfromnasopharyngealaspi-
rates from children with respiratory tract infections. So far,
no speciﬁc diseases have been associated to their infections.
In 2008, a ﬁfth polyomavirus, Merkel cell polyomavirus
(MCPyV), was isolated from the skin of a patient aﬀected
by Merkel Cell carcinoma (MCC) showing its ability to
cause most of the Merkel skin cancers [14]. In addition,
three other polyomaviruses were isolated from no-tumoral
skin, the Human Polyomavirus 6 and 7 (HPyV6, HPyV7),
and the Trichodysplasia Spinulosa-associated Virus (TSPyV)
[15, 16]. Finally, this year, the last polyomavirus, named
Human Polyomavirus 9 (HPyV9), closely related to LPV, was
identiﬁed from the blood and urine of asymptomatic renal
transplant recipients [17]( Table 1).
Viruses that belong to the Polyomaviridae family are
small and nonenveloped. They have icosahedral capsids,
measuring 40.5–44nm in diameter and circular, double-
stranded supercoiled DNA genomes of approximately 5 Kb.
The genome can be divided into two regions, one encoding
the early proteins (the large and small Tumor Antigens) and
another encoding the late, structural proteins Viral Proteins
1–3, which make up the capsid. The late region of BKV,
JCV, and SV40 also encodes an agnoprotein, that seems to be
implicated in viral maturation and microRNAs, which show
a regulatory function in the expression of the Large Tumor
Antigen (LTAg) [18, 19]. The early and late regions are
separated by a noncoding region, the transcriptional control
region (NCCR), which contains the origin of replication and
promoters of viral transcription [20]( Figure 1).
The primary infection of polyomaviruses is usually as-
ymptomatic, probably occurring via respiratory and/or feco-
oral transmission and establishing a latent phase of infection
in the host. JCV and BKV persist in the kidney, while lym-
phoid tissue and the central nervous system (CNS) [21–
23] have been indicated as possible sites of latency. HPyV6,
HPyV7, TSPyV probably persist in the skin and in the lym-
phocytes, but little is known about the cell tropism of these
most recent discovered viruses [24].
Under normal conditions polyomaviruses probably de-
velop mechanisms to evade immune recognition and enable
their latency into their human hosts, but these mechanisms
are unknown. Very recently, Bauman and colleagues demon-
strated that a viral miRNA identical in sequence between
JCV and BKV is involved in immune regulation, resulting
in the escape of the infected cells from the natural killer
cells-mediated killing. In particular, it has been showed that
the miRNA of polyomaviruses targets and downregulates the
stress-induced ligand ULBP3, which is normally recognized
by the killer receptor NKG2D, expressed by NK cells and
other immune cells [25]. Consequently, the reduction of
ULBP3 results in decreased killing of the infected cells
[26].
Thus, reactivation of the infection is closely linked to
the impairment of the immunological state of the host.
There are two possible outcomes to infection of a cell by
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Figure 1: Schematic representation of the polyomaviruses genome
organization. The circular double-stranded DNA genome is length
about 5kb. The early region encodes the functional proteins LTAg
and small T-Antigen, while the late region encodes the structural
proteins VP1-3. The genome of JCV, BKV, and SV40 also encodes
a small structural protein named Agno. The noncoding control
region (NCCR) contains the origin of replication and regulates the
replication and transcription of both the early and late genes.
polyomaviruses. A productive infection occurs when poly-
omavirusesinfectpermissivecells:inthiscase,thevirusentry
into target cells is characterized by nuclear DNA replication
and assembly of the viral capsid followed by the cell lysis.
Onthecontrary,nonproductiveinfectionisestablishedwhen
the virus infects nonpermissive cells blocking the viral DNA
replication and triggering cell transformation (oncogenesis)
[27].
2. Seroprevalence Polyomavirusesin
the Human Population
Polyomavirusesare widely distributed in the worldwide pop-
ulation, and their prevalence has been thoroughly investi-
gated. First, it should be emphasized the high degree of iden-
tity between the genome and aminoacidic sequences of the
human polyomaviruses VP1. For instance, the closely related
viruses BKV and JCV share 78.2% identity of the VP1
amino acid sequences and even greater identity (81.3%) is
shared between BKV and SV40. KIV and WUV show 66% of
sequence homology and are phylogenetically compared with
LPV. They are more distant to JCV and BKV presenting only
28% of amino acid identity [28–30]. Consequently, results of
seroepidemiological studies to determine the prevalence of
antibodies against speciﬁc human polyomaviruses could be
highly heterogeneous considering their possibility to cross-
react with all polyomaviruses species. In addition, the
methods used to measure the speciﬁc seroreactivity toClinical and Developmental Immunology 3
Table 1: Human polyomaviruses.
Nomenclature Year identiﬁed Prevalence in human population Disease associations
BKV 1971 >90% of adults Cystitis, polyomavirus-associated nephropathies, ureteral stenosis
JCV 1971 >70% of adults Progressive multifocal leukoencephalopathy
KIV 2007 55–70% of adults Not deﬁned
WUV 2007 69–80% of adults Not deﬁned
MCPyV 2008 42–70% of adults Merkel cell carcinoma
HPyV6 2010 Not deﬁned Not deﬁned
HPyV7 2010 Not deﬁned Not deﬁned
TSPyV 2010 Not deﬁned Transplant-associated trichodysplasia spinulosum
HPyV9 2011 Not deﬁned Not deﬁned
BKV: BK virus; JCV: JC virus; KIV: Karolinska Institute polyomavirus; WUV: Washington University polyomavirus; MCPyV: Merkel cell polyomavirus;
HPyV6: human polyomavirus 6; HPyV7: human polyomavirus 7; TSPyV: trichodysplasia spinulosum polyomavirus; HPyV9: human polyomavirus 9.
human polyomaviruses are diﬀerent, including virus par-
ticles antigen assay, enzyme, linked immunosorbent assay
(ELISA), hemoagglutination inhibition assay, and immune
electron microscopy [31].
In general, serological population surveys for the detec-
tion of antibodies indicates that seroconversion to human
polyomaviruses takes place early in life, 5 to 7 years for BKV,
with conversion to JCV occurring later. Little is known about
theoccurrenceoftheexposurefortheothernewlydiscovered
human polyomaviruses [30, 32–35]. Kean and colleagues
determined the seroprevalence for LPV (14%), MCPyV
isolate 350 (23–34%), KIV (56%), and WUV (54%) in a
group of 721 young children, conﬁrming that also, for these
viruses, the seroconversion may occur during the childhood
[9].SerologicalevidenceofexposuretoMCPyVinchildhood
has been also reported by Chen et al. who observed a
seroprevalence of 35% in children 4 to 13 years of age and
by Tolstov et al. who described a seroprevalence of 34% in
subjects under the age of 21 [36, 37]. The seroprevalence of
TSPyV was estimated as 5% among children aged 1–4 years,
rising to 48% at 6–10 years [38].
The reported adult levels of seroprevalence vary between
40 and 95% for BKV, between 32 and 95% for JCV, between
54% and 91% for both KIV and WUV, and between 25 and
88% for MCPyV [9, 35, 39–43]. LPV and LPV-related virus
werereportedtobepresentinthehumanpopulationatlower
level, about 15–20% of adults [9]. Only few seroprevalence
data are reported for SV40 testing around 2–10% in the
diﬀerent geographic areas [44, 45].
3. Tumor Associationof
HumanPolyomaviruses
Research on the role of polyomaviruses in development of
neoplasms began in 1953 when Gross isolated a virus, from
a mice lymphoma, that induced an identical tumour when
infected into newborn mice [46]. The virus, identiﬁed as
murine polyomavirus (mPyV), became the archetypal mem-
ber of Polyomaviridae family [2].
The ability of the polyomavirus SV40 to transform
diﬀe r e n tc e l lt y p e sf r o mm a n ys p e c i e sa n dt oc a u s et u m o u r s
in animals model was described in 1960 [47]. To date, the
transforming properties of SV40 have been well character-
izedandtheyhavebeenusedasmodelstostudythepotential
oncogenicity of all other human polyomaviruses.
Polyomaviruses have been found associated with speciﬁc
tumor types such as brain and bone tumors, mesotheliomas,
and lymphomas and with kidney diseases. Speciﬁcally, they
can reproduce diﬀerent types of brain tumours (e.g., medul-
loblastomas, neuroblastomas, astrocytomas, and neuroecto-
dermal primitive tumours) when intracerebrally inoculated
in rodents and monkeys [48, 49].
It has been demonstrated by several in vitro studies that
the main factor implicated in cell transformation and tum-
our development is the early protein LTAg. LTAg is a mul-
tifunctional protein, fundamental for the viral life cycle of
polyomaviruses, because it regulates the viral genome repli-
cationandgeneexpression [50].Theearlyregulatoryprotein
LTAg is functionally divided in several domains, deﬁned,
from the N-terminal to the C-terminal, as follows: the DNaJ
domain, linking to the cellular factor HSc70; the LXCXE
motif, that speciﬁcally binds and inactivates the Rb family
members; the NLS domain, that is necessary for the nuclear
localization of the protein; the Helicase domain; ﬁnally,
the p53 binding domain [27, 51–53]( Figure 2). All these
domains cooperate in binding to and inactivating cellular
proteins that prevent transition into S phase. Consequently,
the virus, that needs the S phase in order to replicate, inhibits
itself replication.
Transgenic mice with the polyomaviruses LTAg gene
under the control of the early viral promoter have developed
brain tumours, such as neuroblastomas and medulloblas-
tomas [54–56]. The transforming activity of LTAg protein
is due to the fact that it can bind and inactivate cellular
tumour suppressor proteins, such as p53 and pRb [57, 58].
Besides these mechanisms of tumourigenicity, which have
been analyzed in depth, it has also been shown that LTAg
is able to deregulate the cell cycle also by interacting with
beta-catenin, a component of the Wnt signal pathway, and
enhancing the expression of c-myc [59]. LTAg can bind
IRS-1, which is translocated in the cell nucleus, where it
cooperates in the process of malignant transformation [60].
Finally, LTAg can bind HSc70, which aﬀects the cell cycle.4 Clinical and Developmental Immunology
DnaJ NLS
Hsc70
pRb 
family
LXCXE
Ori binding Zn ATPase
Helicase
p53
p53 binding domain
Figure 2: Polyomaviruses LT Ag structure. The functional domains are deﬁned as follows: DnaJ domain that binds cellular Hsc70, LXCXE
motif that binds the proteins belonging to the pRb family, NLS domain, that is the nuclear organization signal, Helicase domain, and p53
binding domain, that binds the p53 cellular suppressor protein.
Polyomaviruses LTAg is also able to promote mutagenic
events and chromosomal instability in B lymphocytes and
morphologicalchanges,suchasmultinuclei,aneuplodia,and
polyplodia in transgenic mice [61, 62].
LTAg DNA belonging to JCV, BKV, and SV40 has been
found in diﬀerent types of human tumours, such as brain
tumours (medulloblastomas, astrocytomas, ependymomas,
oligodendrogliomas, and glioblastomas), bone tumours, col-
orectal carcinoma, urinary tract tumours, and lymphomas.
Moreover, the LTAg, expressed protein has also been identi-
ﬁed and localized in almost all the types of above-mentioned
tumours [63–67], showing that the virus is able to express
the oncogenic protein in the host and to cooperate in cell
transformation.
The transforming properties of the very recently dis-
covered KIV and WUV have been tested only by a few
groups, but the results are preliminary. On the contrary,
MCPyV, since its discovery, has been seriously thought as a
candidateetiologicalagentinthedevelopmentofMerkelCell
Carcinoma (see below) (Table 2).
4.Immunityto Polyomaviruses-Induced
Tumours:The PolyomavirusMouseModel
The role of the immune surveillance in polyomaviruses
reactivation is essential, since the virus-induced pathology
mainly occurs in immunocompromised hosts. However,
except for molecular-epidemiological studies, there is little
information about the role of innate immunity related to
polyomaviruses, and how the innate immune system handles
the virus, whereas more information could be obtained
regarding the adaptive immunity.
In addition, because polyomaviruses have a narrow host
range that restricts productive infection to their natural
hosts, the only tractable system for studying polyomaviruses
pathogenesis and immunity is the mPyV infection model.
Since its discovery and given the ease of genome manipu-
lation and expansion in tissue cultures, the mPyV has been
used as infection model for the human polyomaviruses.
When inoculated into immunocompromised adult mice or
newborn mice of diﬀerent inbred strains, polyomavirus
induces multiple tumours that may arise from more than a
dozen diﬀerent cell types [68, 69].
The main study on the role of the innate immune
response to the polyomaviruses infection in the contest of
susceptibility to virus-induced tumours has been published
several years ago, by Velupillai and colleagues [70, 71]. They
Table 2: Polyomaviruses-associated tumors.
Virus Cancer Viral product
JCV
brain tumors DNA, RNA, protein
Lymphoma (Hodgkin disease) DNA, protein
Leukemias DNA
Colorectal carcinoma DNA, protein
Gastric cancer DNA
Lung cancer DNA, RNA, protein
Esophageal carcinomas DNA, protein
Prostate cancer DNA, protein
Tongue carcinoma DNA, protein
BKV
Brain tumors DNA, RNA, protein
Bone tumors DNA, RNA
Insulinomas DNA
Kaposi’s sarcoma DNA
Urinary tract tumors/bladder
tumors DNA, RNA, protein
Adrenal adenoma DNA
Genital tumors DNA
Renal carcinoma DNA
Prostate cancer DNA, protein
SV40
Brain tumors DNA, RNA, protein
Mesotheliomas DNA, RNA, protein
Bone tumors DNA
Lymphomas DNA
Leukemias DNA
Urotheliomas DNA
Breast cancer DNA, protein
M C P y V M e r k e lc e l lc a r c i n o m a D N A ,p r o t e i n
KIPyV Not done —
WUPyV Not done —
studied two diﬀerent inbred strains of mice, infected with
mPyV. The ﬁrst strain, known as BR mice, was resistant
to the tumour, because of an antitumor immune response
mediated by CD8+ T cells speciﬁc for a peptide derived
from the viral middle T-antigen. The eﬀective production
of IL-12 and of IFN-gamma allowed an eﬀective cell-
mediated immunity. The second strain, indeed, called PE
mice, was highly susceptible to the tumour and transmitted
its susceptibility as a dominant trait in crosses with BR mice.Clinical and Developmental Immunology 5
This susceptibility was shown to be due to the absence of a
type 1 cytokine response, leading to a failure to sustain virus-
speciﬁc cytotoxic T-lymphocytes. PE mice, in fact, secreted
IL-10, with no detectable production of IFN-gamma, and,
only after administration of IFN-gamma and recombinant
IL-12 to newborn mice, cytotoxic activity was restored and a
r e d u c t i o ni nt u m o u r sf r e q u e n c yw a sa c h i e v e d[ 72].
In addition, Lowe and colleagues demonstrated the
importance of the innate immunity in increasing the
immune response against SV40 LTAg, using mice model,
aﬀected with SV40 induced-pulmonary metastasis. They
reported upregulation of expression of inﬂammatory
cytokines, such as TNFalpha, IL4, IL2, and RANTES, after
tumorigenic growth and observed that it was correlated with
beneﬁcial reactions. Probably, these inﬂammatory mediators
induced NK cells activation that led to the destruction of
malignant cells [73].
The role of NK cells and γδT cells in killing tumor cells
was also investigated by Mishra in colleagues in 2010. They
observed that mice lacking αβT cells are protected from the
formation of tumors induced by the mPyV if they have
γδT cells and NK cells. In addition, mice lacking both cells
develop the tumors earlier than mice that have only NK cells.
Additional experiments showed that NK cells and γδTc e l l s
mount antitumor but not antiviral responses, since they do
not have any eﬀects on the amount of persisting virus [74].
Manystudieshaveindicatedthatmultiplecomponentsof
the immune system contribute to limiting mPyV replication,
includingearlyinductionofantibodies,recruitmentofCD4+
and CD8+ T cells, and generation of humoral immunity.
Firstly, it has been observed that congenitally thymus-
deprived nude mice have increased susceptibility to virus
oncogenesis, demonstrating that T cells prevent the tumours
induction.Then,theresultswereenrichedbytheobservation
that knockout mice with complete lack of major histocom-
patibility complex (MHC) class I molecules were mPyV
tumour-susceptible. Consequently, MHC-class I-restricted
CD8+ T cells are thought to be the primary eﬀectors-cell
population, during polyomaviruses infection [75, 76].
Since polyomaviruses infection is persistent in the host,
the immune system has to face with repetitive antigen en-
counter. In this situation of chronic antigen exposure, host
mechanisms may come into play to intentionally downregu-
late CTL activity to prevent widespread destruction of anti-
gen-bearing cells. Thus, peripheral tolerance mechanisms
are engaged to deregulate antigen-speciﬁc CD8+ Tc e l lr e -
sponses. Many models of tolerance come from pathogenic
persistent viruses in humans, including HCV, EBV, HIV,
and HBV [77–80]. In these cases, CD8+ T cells gradually
lack functional competence and weaken their cytotoxicity.
However, the premature termination of antiviral CD8+ T
cell function for oncogenic viruses can cause serious conse-
quences. In transgenic mice, in fact, T-cell response is com-
promised by either central or peripheral tolerance [81, 82].
T h er o l eo fC D 4 + T lymphocytes in immunity to virus-
induced tumours has been less studied, but it is thought
to provide help for MHC-class I-restricted CD8+ cytotoxic
(antitumour) T lymphocytes. Kennedy et al. evaluated the
role of T-cell subsets in tumour immunity induced by
recombinantSV40T-Agwithinanexperimentalmurinepul-
monary metastasis model. By depleting mice of either CD4+
or CD8+ T cells, indications were found that CD4+ Tc e l l s
but not CD8+ T cells were critical in the production of
antibodies to LTAg and in tumour immunity. Then, it was
shown that IgG1 was the dominating IgG subclass indicating
that Th2 type T-helper cells were involved [83]. CD4+ Tc e l l s
are also required for recruitment of naive antiviral CD8+ T
cells during persistent mPyV infection [84]. Two dominant
mPyV-speciﬁc CD4+ T cells populations are present, one
directed toward an epitope derived from the LTAg and
the other from the VP1, that diﬀered quantitatively and
qualitatively during the course of infection. They are both
stably maintained during persistent infection, but the VP1-
speciﬁc CD4+ T-cell response is higher than that against
LTAg. In addition, mPyV-speciﬁc CD4+ T cells, although
not essential for expansion of CD8+ T cells during acute
infection, are indispensable for de novo priming of antiviral
naive CD8+ T cells in persistently infected hosts [85].
The potential cytotoxic activity of polyomavirus-speciﬁc
CD4+ T cells has been studied in BKV-seropositive subjects,
who also showed BKV-speciﬁc CD4+ and CD8+ cells. After
expansioninculture,infact,themajorityoftheBKV-speciﬁc
CD4+ T cells was shown to express CD40, to secrete both
IFN-gamma and TNF-alpha, to contain both granzyme A
and granzyme B, and to degranulate/mobilize CD107 in
response to antigen-speciﬁc stimulation [86].
Moreover, tumour induction was found to be age depen-
dent and this age-related resistance to tumour induction was
immunologically mediated as animal models that have been
immunocompromised by X-irradiation become susceptible
to tumour induction.
5.PotentialClinical
Application of Immunotherapy
One of the strategies that has been used for adoptive
immunotherapy of cancer identiﬁes, isolates, and expands in
vitro CD8+ T-cells responsive to human tumours antigens.
However, few immunotherapeutic approaches that target the
recruitment of tumor reactive CD8+ T cells have been eﬀec-
tive against solid tumors. Surely, tumors of the CNS provide
a unique challenge to immunotherapy due to more stringent
regulation of lymphocyte circulation and the potential for
the negative side eﬀects induced by T-cell eﬀector func-
tions. In 2008, a mouse model of autochthonous brain
cancer to assess adoptive immunotherapeutic approaches of
polyomavirus-induced disease was examined. This model
consisted of SV40 LTAg transgenic mice SV11 which develop
spontaneous choroid plexus tumors due to expression of
full-length LTAg and lack the endogenous CD8+ Tc e l l s
that in nontransgenic mice respond to the three diﬀerent
LTAg epitopes, I, II/III, and IV. In the model, donor T cells
against the immunodominant epitope IV are subject to the
potential eﬀects of peripheral tolerance and the immuno-
suppressive tumor environment following adoptive transfer
into SV11 mice with both minimal disease and advanced
stagetumors.Theperformedexperimentsdemonstratedthat6 Clinical and Developmental Immunology
LTAg-speciﬁc CD8+ T cells from immune donors accumu-
latedatthetumorsiteandareassociatedwithreducedtumor
burden and extension of the lifespan. In addition, it has
been shown that IFN-gamma component donor cells play a
major role in the immune-mediated control of established
autochthonous tumors in CNS [87, 88].
Many other studies are needed to conﬁrm the feasibility
of immunotherapy approaches to polyomavirus-induced
tumors.
6.A SpecialFocus on
the Merkel CellPolyomavirus
Feng and colleagues have published the identiﬁcation of
Merkel Cell Polyomavirus (MCPyV) DNA in the in Merkel
Cell Carcinoma samples (MCC) in 2008. The innovative
method used consists in generating cDNAs library from tar-
get cell transcripts, in pyrosequencing the DNA and ﬁnally
in screening all the sequencing-data in order to identify non
human transcripts. The detected non human sequence was
a fusion transcript between an unknown virus LTAg and a
human receptor tyrosine phosphatase. Further investigation
by the same group led to the sequence of the complete ge-
nomeofthispreviouslyunknownpolyomavirus,theMCPyV
[14].
MCC is a neuroectodermal tumour arising from me-
chanoreceptor Merkel Cells that are present in the skin of the
limbs and face and around hair follicles [89]. It is a rare and
aggressive skin cancer, unusual before the age of 50, with an
incidence rate of 0.44 cases per 100,000 subjects in the USA;
however, its incidence is dramatically increasing, tripling
from 1986 to 2001. The risk factors for the development of
MCC comprise excessive UV light exposure, age >50 years
old and immunosuppressive state of the host [89–92].
The paper by Feng and colleagues reported the detection
of sequences in 8 of 10 (80%) MCC tumours, but only in
9 of 84 (10,7%) control tissues, including skin tissue. In
addition, the ability of the MCPyV to integrate into the
human genome was described: in six of eight positive tissues,
the MCPyV genome was integrated within the host genome
in a clonally pattern; metastatic cells also carried the same
integration pattern. On the contrary, genome was present
in the episomal form in all the other nontumour positive
tissues. All the above-mentioned virus characteristics led
the scientiﬁc community to state that MCPyV may be a
candidate causative agent in the etiopathogenesis of MCC.
Moreover, it was observed in a subsequent study that the
LTAg ampliﬁed from 9 out of 9 MCC tissues had a mutation,
resulting in a truncated protein, that lacked the helicase
domain. On the contrary, the wild-type form of LTAg was
detected in non-MCC tissues [14, 93–96].
Since the initial report, many other studies, have been
published around the world, conﬁrming the presence of this
polyomavirusinMCC.Inparticular,theyreferthattherange
of virus recovering from MCC fresh, frozen, formalin-ﬁxed,
or paraﬃn-embedded tumour samples varies between 24%
and 100%, even if the data cannot be compared because of
the diﬀerent methodologies employed [97].
The prevalence of MCPyV in normal tissues or tumours
other than MCC are more contrasting. The virus genome
has been detected in skin samples with variably frequency
ranging from 10% to 30%, whereas other studies reported
p r e v a l e n c er a t e so fM c C o yD N Au pt o9 6 % ,i nc u t a n e o u s
swabs [98]. The virus was also searched in samples from
neuroendocrine tumours from a variety of anatomic sites,
colorectal cancer, prostate cancer, hematopoietic neoplasm,
central nervous system tumours, mesothelioma, and many
others, but none of the studies showed an association
betweenvirusanddisease.Inaddition,thereportednumbers
of virus genome copies per MCC tumour cell are much
higher (range 0.8–173/cell) [95, 99] than the highest value
obtained for the other MCPyV genome-positive samples
(0.01–0.0001 genome copies/cell). Finally, the antibody titres
against MCPyV are much higher in MCC patients compared
to healthy controls [100, 101]
The proposed mechanism by which MCPyV induces
MCC in virus-positive tumours is based on the activity of
the truncated LTAg: it retains the region with oncogenic
potential such as the DnaJ domain and the retinoblastoma
binding pocket but lacks the domain supporting the viral
DNA replication. This is important because the loss of repli-
cationactivityuponintegrationinMCCdemonstratesthatis
not simply a “passenger virus” that happens to grow well in
MCCcells[93,96,102].Moreover,theimmunoprecipitation
assays have shown that truncated LTAg is able to bind to
Rb protein, a critical step into carcinogenesis event. The
production of LTAg is necessary for the proliferation of
MCPyV-positive MCC, since it has been demonstrated that
the silencing of the virus gene by short-hairpin RNA causes
growth arrest and/or cell death of the speciﬁccell lines. Thus,
it has been proposed that MCPyV plays an important role in
the MCC pathogenesis by means of viral integration into the
host and speciﬁc mutations in the LTAg region that retains
the Rb-binding capacity, eliminating the possibility of viral
replication.
7.Immunobiology of MCPyV-PositiveMCC
As for the other human polyomaviruses, a strong link
between MCPyV-positive MCC and the immune system has
been suggested. Patients with immune system impairment,
such as HIV-related immunodeﬁciency, drugs-associated
immunosuppression, or forms of chronic leukaemia, are at
up to 50-fold increased risk of developing MCC [89, 90].
Additionally, it has been shown that MCC tumours regress
following improvement in immune function.
As already reported above, the high and wide seropreva-
lence of MCPyV suggests that the exposure to the virus
is a common event in the human population and that
the capsid virus proteins are well recognized by the host
immune system. However, MCPyV-positive MCC patients
show a higher titer of antibodies against VP1, compared
to the healthy population or to MCPyV-negative MCC pa-
tients, probably due to the exposure to an higher MCPyV
viral load. In addition, the presence of a strong humoral im-
mune response to MCPyV has been associated with aClinical and Developmental Immunology 7
better prognosis of the tumours, perhaps showing that host
immune system plays a critical role also in the remission of
the infection [103].
Interestingly, Paulson and colleagues collected sera from
205 MCC cases and from 530 healthy controls and screened
them for T-Ag reactivity, demonstrating that IgG antibody
reactivity to the MCPyV LTAg and st-Ag oncoproteins
was signiﬁcatively associated with MCC. In addition, they
observed rapid changes in LTAg titre corresponding to the
diﬀerent disease burden: titres were highest when patients
were sickest, suggesting that antibodies to LTAg are not pro-
tectiveagainstdiseaseprogression.Theauthorshypothesized
thattherapidturnoverofIgGantibodiesrecognizingLTAgin
MCC patient may be due to the instability within the B-cell
population, caused by ineﬀective priming within the tumour
microenvironment [104]. In contrast to capsid proteins that
are highly visible to the humoral immune system, T-antigen
oncoproteins are not present in viral particles, are only
expressed after viral entry into host cells, are located in the
nucleus [105], and are thus less likely to trigger an antibody
response except in the setting of dying or diseased tissue
(such as a tumour that persistently expresses the LTAg).
Very recently, it was observed that MCPyV-speciﬁc T-
helper cells secrete the IL13, IL10 cytokines, and IFN-
gamma, that have a strong tumour-suppressing and antiviral
functions [106].
The speciﬁc immune response mediated by T cells has
also been documented in MCPyV-positive MCC patients.
A study published recently has shown that intratumoral
inﬁltration of CD8+ lymphocytes is a factor of improved
prognosis of the disease. The same study showed also an
overexpression of genes encoding cytotoxic granules such as
granzymes, chemokine CCL19, and many lymphocyte-acti-
vation molecules in patients with improved survival [107].
8. Conclusions
The recent identiﬁcation of many components of the Poly-
omaviridae family that are able to infect humans represents
a strong incentive for the scientiﬁc community to improve
and increase the research on the oncogenic potentialities
of these viruses. The ubiquity and persistent nature of
polyomaviruses make them very challenging in order to
deﬁne the mechanisms of their pathogenicity. In particular,
since the association between the viral aetiology of the
tumours and the state of the host immune system is well
established, it is urgent to focus future studies on the nature
of the relationship between the host immune system and
polyomaviruses infection.
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